Descartes 012
Alternative Names: Descartes-012Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Cartesian Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Multiple myeloma
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
- 28 Aug 2020 Preclinical trials in Autoimmune disorders in USA (Parenteral) before August 2020 (Cartesian Therapeutics pipeline, August 2020)